AUTHOR=Bayer Jason D. , Boukens Bastiaan J. , Krul Sébastien P. J. , Roney Caroline H. , Driessen Antoine H. G. , Berger Wouter R. , van den Berg Nicoline W. E. , Verkerk Arie O. , Vigmond Edward J. , Coronel Ruben , de Groot Joris R. 

TITLE=Acetylcholine Delays Atrial Activation to Facilitate Atrial Fibrillation

JOURNAL=Frontiers in Physiology

VOLUME=10

YEAR=2019

URL=https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2019.01105

DOI=10.3389/fphys.2019.01105

ISSN=1664-042X

ABSTRACT=<sec><title>Background</title><p>Acetylcholine (ACh) shortens action potential duration (APD) in human atria. APD shortening facilitates atrial fibrillation (AF) by reducing the wavelength for reentry. However, the influence of ACh on electrical conduction in human atria and its contribution to AF are unclear, particularly when combined with impaired conduction from interstitial fibrosis.</p></sec><sec><title>Objective</title><p>To investigate the effect of ACh on human atrial conduction and its role in AF with computational, experimental, and clinical approaches.</p></sec><sec><title>Methods</title><p>S1S2 pacing (S1 = 600 ms and S2 = variable cycle lengths) was applied to the following human AF computer models: a left atrial appendage (LAA) myocyte to quantify the effects of ACh on APD, maximum upstroke velocity (V<sub><italic>max</italic></sub>), and resting membrane potential (RMP); a monolayer of LAA myocytes to quantify the effects of ACh on conduction; and 3) an intact left atrium (LA) to determine the effects of ACh on arrhythmogenicity. Heterogeneous ACh and interstitial fibrosis were applied to the monolayer and LA models. To corroborate the simulations, APD and RMP from isolated human atrial myocytes were recorded before and after 0.1 μM ACh. At the tissue level, LAAs from AF patients were optically mapped <italic>ex vivo</italic> using Di-4-ANEPPS. The difference in total activation time (AT) was determined between AT initially recorded with S1 pacing, and AT recorded during subsequent S1 pacing without (<italic>n</italic> = 6) or with (<italic>n</italic> = 7) 100 μM ACh.</p></sec><sec><title>Results</title><p>In LAA myocyte simulations, S1 pacing with 0.1 μM ACh shortened APD by 41 ms, hyperpolarized RMP by 7 mV, and increased V<sub><italic>max</italic></sub> by 27 mV/ms. In human atrial myocytes, 0.1 μM ACh shortened APD by 48 ms, hyperpolarized RMP by 3 mV, and increased V<sub><italic>max</italic></sub> by 6 mV/ms. In LAA monolayer simulations, S1 pacing with ACh hyperpolarized RMP to delay total AT by 32 ms without and 35 ms with fibrosis. This led to unidirectional conduction block and sustained reentry in fibrotic LA with heterogeneous ACh during S2 pacing. In AF patient LAAs, S1 pacing with ACh increased total AT from 39.3 ± 26 ms to 71.4 ± 31.2 ms (<italic>p</italic> = 0.036) compared to no change without ACh (56.7 ± 29.3 ms to 50.0 ± 21.9 ms, <italic>p</italic> = 0.140).</p></sec><sec><title>Conclusion</title><p>In fibrotic atria with heterogeneous parasympathetic activation, ACh facilitates AF by shortening APD and slowing conduction to promote unidirectional conduction block and reentry.</p></sec>